NCT05358821View on ClinicalTrials.gov

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

April 10, 2024

Conditions
Huntington Disease
Interventions
DRUG

SAGE-718

SAGE-718 oral softgel lipid capsules

DRUG

Placebo

SAGE-718-matching oral capsules

Trial Locations (14)

10027

Sage Investigational Site, New York

19104

Sage Investigational Site, Philadelphia

20057

Sage Investigational Site, Washington D.C.

21218

Sage Investigational Site, Baltimore

27599

Sage Investigational Site, Chapel Hill

33431

Sage Investigational Site, Boca Raton

33602

Sage Investigational Site, Tampa

35233

Sage Investigational Site, Birmingham

45221

Sage Investigational Site, Cincinnati

60612

Sage Investigational Site, Chicago

77030

Sage Investigational Site, Houston

80113

Sage Investigational Site, Englewood

90720

Sage Investigational Site, Los Alamitos

H2X 3E4

Sage Investigational Site, Montreal

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY